JP Morgan Healthcare Conference

January 9th, 2023

Matt Trerotola - Chief Executive Officer
Ben Berry - Chief Financial Officer
Derek Leckow - Vice President, Investor Relations
This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, including the anticipated benefits of our recently completed separation of Enovis’ fabrication technology and specialty medical technology businesses (the “Separation”) and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the scope and duration of the outbreak, the rise, prevalence and severity of variants of the virus, material delays and cancellations of medical procedures, the nature and effectiveness of actions and restrictive measures by governments, businesses and individuals in response to the situation, and their impact on the global and regional economies, financial markets, creditworthiness and financial viability of customers, and overall demand for our products; the war in Ukraine and escalating geopolitical tensions as a result of Russia’s invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; supply chain disruptions; the potential to incur significant liability if the Separation is determined to be a taxable transaction; the ability to realize the anticipated benefits of the Separation, the financial and operating performance of the company following the Separation; other impacts on Enovis’ business and ability to execute business continuity plans; and the other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.
Key Takeaways

• Foundation in attractive orthopedic market with favorable market trends
• Unique MedTech player with two strong segments and proven business system
• Clear strategy and momentum for HSD organic growth fueled by innovation
• Significant margin improvement path through mix, productivity and scale
• Acquisition opportunities and ample capital to accelerate growth and compound value
• Demonstrated track record and strong progress toward strategic goals
Enovis™ is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows.

Powered by a culture of continuous improvement, extraordinary talent and innovation, we ‘create better together’ by partnering with healthcare professionals.

Our extensive range of products, services and integrated technologies fuels active lifestyles.

#CreatingBetterTogether
Enovis: An Innovation and Growth Driven MedTech Company

Revenue and Segment Mix

$1.6b
TTM\(^1\)

<table>
<thead>
<tr>
<th>Segment</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>70%</td>
</tr>
<tr>
<td>OUS</td>
<td>30%</td>
</tr>
<tr>
<td>Recon</td>
<td>33%</td>
</tr>
<tr>
<td>P&amp;R</td>
<td>67%</td>
</tr>
</tbody>
</table>

Two Attractive Business Segments

Fast growing reconstructive (Recon) platform
- DJO Surgical DD growth engine in US, leading in Shoulder and rapid adoption in Knee & Hip
- Globalized footprint and offering through acquisition of Mathys
- Expansion into attractive Foot & Ankle market in 2021

Global leader in prevention & recovery (P&R)
- Global leader in rigid bracing and soft goods
- Reshaping care path with MotionMD\(^\circledast\) and MotioniQ™ digital solutions
- Technology leader in recovery sciences with broad offering in advanced rehabilitation modalities

Positioned for significant growth and value creation

1: Trailing 12 months: 9/30/22 ENOV as reported revs plus MedTech segment revs for 3 months ended 12/31/2021
Addressing Large, Attractive Market

Enovis competes in half of the $53B Orthopedics market and “touches” nearly all

<table>
<thead>
<tr>
<th>Our Recon served markets</th>
<th>Est. Market Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knee</td>
<td>3-4%</td>
</tr>
<tr>
<td>Hip</td>
<td>7-8%</td>
</tr>
<tr>
<td>Extremities</td>
<td>6-7%</td>
</tr>
<tr>
<td>Trauma</td>
<td>3-4%</td>
</tr>
<tr>
<td>Sports Medicine</td>
<td>6-7%</td>
</tr>
<tr>
<td>Spine</td>
<td>3-4%</td>
</tr>
<tr>
<td>Biologics</td>
<td>2-3%</td>
</tr>
</tbody>
</table>

Surgical Implants and Instrumentation
Prevention & Rehabilitation (P&R)

Market Growth Trends Provide Runway

- Aging but active population, rising obesity
- Transitioning to outpatient care
- Innovation improving the quality of care

Enovis is well-positioned in segments with strong long-term growth drivers

Established Brands and Accelerating Innovation

Prevention & Recovery Segment

- Recovery Sciences
- Bracing
- ~$1.1b TTM¹

- #1 Globally in Bracing
- #1 Globally in Rehab
- #2 In Bone Stimulation

Reconstructive Segment

- Foot & Ankle
- Hip
- Knee
- ~$0.5b TTM¹

- #3 In US Shoulder
- DD Organic Growth

Market leading position in P&R and fast-growing Recon products

Aircast®, Chattanooga®, DonJoy®, Empower Dual Mobility™, Empower®, DynaNail™, Litetric®, Altivate®,

¹: Trailing 12 months: 9/30/22 ENOV as reported revs plus MedTech segment revs for 3 months ended 12/31/2021
Uniquely Positioned Across Full Ortho Care Continuum

**PREVENTION**
- Off-loading braces
- Back braces
- Cold therapy

**SURGICAL**
- Shoulders
- Knees
- Hips
- Foot/Ankle

**RECOVERY**
- Post-op braces
- Walker boots
- Cold therapy

**PERFORMANCE**
- Athletic braces
- Muscle stimulation

**REPAIR**
- Brand leverage with hospitals, surgeons, clinicians, patients
- Digital workflow solutions for clinics
- Connected medicine solutions for patient journey
- Full “episode of care” partner to ambulatory surgery centers (ASC)

**REHAB**
- Electrotherapy
- Laser therapy
- Heat/cold therapy
- Traction devices

Leveraging broad and deep market access and technology for strategic advantage
Scaled and Agile in Fragmented Industry

**Competitive Ortho Landscape**

**Enovis’ Attractive Position**

- Big enough for healthy margins but additional room to scale
- Small enough to operate like an innovator
- Can select most valuable growth paths
- Ample bolt-on opportunities, attractive path to market/scale for innovators

Enovis is positioned for share gain, scale, and expansion

**Ortho Revenue**

- >$3B
- $0.5 - $3B
- <$0.5B

*30 players in $0.1-0.5B range
~1,000 pre-revenue or early revenue players

1: 2021 revenue, as reported.
Strong Leadership Team, Deep MedTech Experience

**Board of Directors**

- Mitch Rales: Chairman, Colfax, Danaher Co-Founder
- Matt Trerotola: CEO
- Brady Shirley: President & COO
- Barbara Bodem: Former SVP & CFO of Hillrom
- Liam Kelly: CEO of Teleflex Incorporated
- Angie Lalor: Former SVP of HR, Danaher, 3M
- Phil Okala: COO, UPenn Health Systems
- Christine Ortiz: Prof. of Materials Sciences and Engineering, MIT
- Clay Perfall: Operating Executive, Tailwind Capital
- Rajiv Vinnakota: President, Institute for Citizens & Scholars
- Sharon Wienbar: Former Partner, Scale Venture Partners

**Enovis Senior Leadership Team**

- Matt Trerotola: CEO
- Brady Shirley: President & COO
- Ben Berry: EVP & CFO
- Dan Pryor: EVP BD, Strategy
- Patty Lang: CHRO
- Brad Tandy: General Counsel

© 2023 Enovis Corporation
Proven and Powerful Business System

Our Enovis Growth eXcellence business system is a set of tools, processes, and culture, incorporating continuous improvement to drive and fuel growth.

Recent Activity

- >40% reduction in recordable safety incidents

Step-change bracing customer service improvement

- >100% improvement in shipping productivity in largest DC
Establishing A High-Value MedTech Growth Company

Enovis Sales Performance & Goals

Clear path to $2B and beyond with HSD organic growth and expanded margin profile

1: Pro forma revenues for 2021, based Colfax Corp. Medical Technology segment revenues of $1,426.1MM for the year ended December 31, 2021, plus management’s estimates of full year contributions from Mathys, Trilliant and Medshape acquisitions.
Strategy for Compounding Shareholder Value

Strategic Pillars...

- Shaping P&R for sustained MSD Growth
- Rapidly Expanding High Growth & Margin Recon Platform
- Expanding Margins with EGX and Scale
- Accelerating Growth through M&A

...enabled by:

- Innovation for better patient outcomes
- Digital technologies for better workflows
- Lean, resilient supply chains with EGX
- Powerful, scaled commercial engines
Shaping P&R Platform for Sustained MSD Growth

Re-establishing Strong Innovation Engine

Connecting Workflows with Digital Healthcare & Connected Medicine

Investing in Attractive Rehab/Recovery Modalities

- 2018 7% Vitality¹ Index
- 2021 15% Vitality¹ Index

Launched connected knee brace and sleeve in 2022

LiteCure™ Laser

2X Expansion in direct sales team

¹: Vitality defined as new product revenue (introduced in last 3 years) as a percentage of total revenue. Does not include P&R class 3 bone stimulation revenues.
P&R Growth Has Stabilized

Stabilization Efforts

- Re-established customer service levels
- Increased vitality
- Leveraging clinic workflow position and channel strength for share gains

Organic Sales Growth

- 3% CAGR
- 2%
- -4%
- -13%
- 14%
- 4.0%

Acquisition & Turn around

Above market

2013-17 2018 2019 2020 2021 2022 9M

LSD+ ⇔ MSD

Organic Revenue Growth

Investment and improvements driving sustained above-industry growth

1: Adjusted for constant currency, excludes acquisition and discontinued business lines.
## Rapidly Expanding High Growth & Margin Recon Platform

<table>
<thead>
<tr>
<th>Leverage Demonstrated Outcomes</th>
<th>Continue Pace of Innovation</th>
<th>Win in the High Growth ASC</th>
<th>Grow &amp; Scale Foot &amp; Ankle</th>
<th>Expand Geographically</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Altivate Reverse® Shoulder</strong>: Breakthrough in range of motion</td>
<td><strong>Expansion in product bag penetration</strong>: ~65% to ~75%</td>
<td><strong>Leverage enabling technologies</strong>: e.g. ARVIS®, ADAPTABLE®</td>
<td><strong>Launch innovative technologies</strong>: e.g. DynaNail®, Arsenal Foot Plating System™</td>
<td><strong>Mathys acquisition</strong>: Nearly doubles addressable market and expands portfolio</td>
</tr>
<tr>
<td><strong>EMPOWR 3D Knee®</strong>: breakthrough in natural kinematics</td>
<td><strong>Launch enabling technology</strong>: e.g. AR, CAS/Robotics</td>
<td><strong>Continuum of care coverage</strong>: Pre, intra &amp; post op offerings</td>
<td><strong>Modernize STAR™ ankle</strong>: Patient Specific Instrumentation &amp; Surface enhancements (e+ poly)</td>
<td><strong>Cross-selling opportunities</strong>: Altivate® &amp; EMPOWR® expansion</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Products aligned to favorable patient profiles</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Continuum of care coverage**: Pre, intra & post op offerings
- **Launch enabling technologies**: e.g. ARVIS®, ADAPTABLE®
- **Modernize STAR™ ankle**: Patient Specific Instrumentation & Surface enhancements (e+ poly)
- **Mathys acquisition**: Nearly doubles addressable market and expands portfolio
- **Cross-selling opportunities**: Altivate® & EMPOWR® expansion
- **Expansion in product bag penetration**: ~65% to ~75%
- **Launch enabling technology**: e.g. AR, CAS/Robotics
- **Products aligned to favorable patient profiles**
## Recon Double-Digit Growth Formula

<table>
<thead>
<tr>
<th></th>
<th>% of Recon Market</th>
<th>Market Growth(^1)</th>
<th>Projected Growth vs. Market</th>
<th>Growth Projection</th>
<th>2022 9M</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Shoulder</td>
<td>~30%</td>
<td>7-8%</td>
<td>~2x</td>
<td>12 – 15%</td>
<td>13%</td>
</tr>
<tr>
<td>US Hip / Knee</td>
<td>~30%</td>
<td>3-4%</td>
<td>3-5x</td>
<td>10 – 15%</td>
<td>16%</td>
</tr>
<tr>
<td>Foot / Ankle</td>
<td>~10%</td>
<td>6-7%</td>
<td>2-3x</td>
<td>15 – 18%</td>
<td>8%</td>
</tr>
<tr>
<td>Int’l Recon</td>
<td>~30%</td>
<td>4-5%</td>
<td>2-3x</td>
<td>7 – 10%</td>
<td>11%</td>
</tr>
</tbody>
</table>

\(^1\) Orthoworld 2021 Orthopedic Industry Annual Report.

Clear track record and trajectory for sustained double-digit organic growth.
Fast-Growing Recon Business with Proven Playbook

- **2X market growth** led by Altivate Reverse and accelerating Altivate Edge anatomic stemless
- **Proven MatchPoint® pre-operative plan and PSI system** in 35%+ of procedures

**Best-in-Class medical education** across segments

**Unparalleled KOL leadership** team

**Aggressive NPI cadence**

Sustained strong DD growth across segments

**US Shoulder Revenue**

- 2013: $100M
- 2014: $120M
- 2015: $140M
- 2016: $160M
- 2017: $180M
- 2018: $200M
- 2019: $220M
- 2020: $240M
- 2021: $260M

14% CAGR 2022 9M 13%

**US Hip / Knee Revenue**

- 2013: $100M
- 2014: $120M
- 2015: $140M
- 2016: $160M
- 2017: $180M
- 2018: $200M
- 2019: $220M
- 2020: $240M
- 2021: $260M

17% CAGR 2022 9M 16%

- **3-5X market growth** powered by Empowr3D® Knee and Taperfill® Hip Stem
- **Great implants** and **enabling technologies** for ASC
Computer Assisted Surgery (CAS) Strategy

Anatomically distinct

Suite of offerings uniquely tooled to each anatomy

Match Point System™

Match Point™ System used in ~30% of Enovis shoulder cases

Best-in-class Pre-Op Planning & PSI¹ for Total Ankle

Unique guidance platform leveraging AR

Spanning entire workflow

End-to-end set of integrated components that can also be used on a standalone basis

Pre-Op / Patient Specific Instrumentation

Intra-Operative Imaging

Surgical Guidance / Robotics

Platform purpose-built for ASC

Optimized for ASC success – effective, efficient and affordable

Low capital costs

Time and Space Efficient

Micro footprint

Enovis enabling technologies will provide a flexible and scalable approach

¹ PSI stands for Patient Specific Instrumentation.
Expanding Margins with Clear Strategy & EGX

aEBITDA Margin (%)

>50bps per year

2021  Mix  Acquisition  Scale  Operating  Leverage  Future

Continuous margin improvement leveraging growth and EGX

Margin Drivers

• Mix benefits generated by growth in Recon
• Scale and synergy from recent acquisitions
• Operating leverage from growth, EGX productivity, COVID recovery and disciplined price/cost management

© 2023 Enovis Corporation
Robust M&A Opportunities to Accelerate Growth

**Expand**
Redefine boundaries
- Expand along Continuum of Care
- Add High-Growth / High-Margin P&R
- Expands Channels
- Enter Logical Clinic-Based Adjacencies

**Extend**
Build out from core
- Expand Geographically
- Add Digital Solutions
- Build around Healthcare Provider
- Enter High-Growth Recon Sub-Segments

- Apply Technology in Other Markets

**Excel**
Win in the core
- Fill Product Line Gaps
- Expand along Continuum of Care
- Enter Logical Clinic-Based Adjacencies
- Expands Channels

**Acquisition Criteria**

- Fuels growth
- Improves gross margin
- Accelerates strategy
- Expands market reach
- Creates scale
Recent M&A Successfully Reshaping Our Business

**Entered Foot & Ankle**
- >$1B Market
- HSD growth category
- Fragmented competition

**MedShape® / Trilliant®**

**AR Surgical Platform**
- Next Gen total joint arthroplasty system
- Footprint and cost positioned for ASC

**MedShape® / Trilliant®**

**ASC Solutions**
- Double digit procedural volume growth
- Provides Surgical assistance

**Arvis™ AR**

**High Growth Modalities**
- HSD growth category
- Synergy opportunities
- Expanded applications

**LiteCure™ Laser**

**Geographical Expansion**
- Drives growth outperformance
- Increased scale benefits
- Direct market penetration

**Geographical Expansion**

**DD+**
Organic Growth

**Accretive**
Gross Margins

**Ability to Scale**

~1.0x net leverage and ~$1b of investment capacity...ample resources to support future growth
Key Takeaways

- Foundation in attractive orthopedic market with favorable market trends
- Unique MedTech player with two strong segments and proven business system
- Clear strategy and momentum for HSD organic growth fueled by innovation
- Significant margin improvement path through mix, productivity and scale
- Acquisition opportunities and ample capital to accelerate growth and compound value
- Demonstrated track record and strong progress toward strategic goals